Literature DB >> 34370095

Treating hypercholesterinemia in a patient with maternally inherited diabetes and deafness (MIDD) by the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab.

Bernd Schultes1,2, Barbara Ernst3, Sebastian M Schmid4,5.   

Abstract

Entities:  

Keywords:  Arteriosclerotic cardiovascular disease; Hypercholesterinemia; MIDD; Mitochondrial; PCSK9 inhibitors

Mesh：

Substances：

Year:  2021        PMID： 34370095     DOI： 10.1007/s00592-021-01776-w

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN： 0940-5429            Impact factor:   4.280


× No keyword cloud information.
  2 in total

1.  Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials.

Authors:  Om P Ganda; Jorge Plutzky; Santosh K Sanganalmath; Maja Bujas-Bobanovic; Andrew Koren; Jonas Mandel; Alexia Letierce; Lawrence A Leiter
Journal:  Diabetes Obes Metab       Date:  2018-07-02       Impact factor: 6.577

2.  Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.

Authors:  Lawrence A Leiter; Bertrand Cariou; Dirk Müller-Wieland; Helen M Colhoun; Stefano Del Prato; Francisco J Tinahones; Kausik K Ray; Maja Bujas-Bobanovic; Catherine Domenger; Jonas Mandel; Rita Samuel; Robert R Henry
Journal:  Diabetes Obes Metab       Date:  2017-10-10       Impact factor: 6.577
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.